2014 ESC WGT/EHRA/EAPCI/ACCA Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary or Valve Interventions

In 2010, the European Society of Cardiology (ESC) Working Group on Thrombosis published a consensus document, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Coronary Intervention (EAPCI), to address the management aspects of this complex clinical scenario. This was followed by a North American consensus document, which had many similarities in management approaches. Since 2010, substantial changes are now evident in stroke prevention in AF, with the introduction of NOACs and greater attention to quality of anticoagulation control as reflected by average time in the therapeutic range (TTR) of the international normalized ratio.

For this update, the Working Group on Thrombosis of the ESC convened a Task Force, with representation from EHRA, EAPCI, and the Acute Cardiovascular Care Association (ACCA), endorsed by the Heart Rhythm Society (HRS) and the Asia Pacific Heart Rhythm Society (APHRS), with the remit to comprehensively review the published evidence available since the 2010 document, to publish a joint consensus document on the optimal antithrombotic therapy management in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions and to provide up-to-date recommendations for use in clinical practice.